Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

OmniaBio Plans Hamilton, Ontario, Manufacturing Operations

10/30/2024
OmniaBio Inc., a cell and gene therapy contract development and manufacturing organization, plans to establish operations in Hamilton, Ontario, Canada. The $145 million project is expected to create 250 jobs.

The new North American cell and gene therapy manufacturing and artificial intelligence Centre of Excellence, located at McMaster Innovation Park, will meet specialized needs such as; critical cold chain logistics, dedicated staff training infrastructure, intelligently designed production flows, and a multi-modality layout facilitating both cell and vector-focused manufacturing.

"OmniaBio is partnering with clients to make these essential therapies more accessible and affordable for patients in North America and worldwide. This new facility puts us in a unique position as a specialist commercial CGT manufacturing leader tackling the toughest disease challenges head-on by combining an experienced team with advanced tools and solutions,” said Mitchel Sivilotti, President and CEO, OmniaBio Inc.

The project is being supported by a loan of up to $40 million through the Invest Ontario Fund.

"With a highly-skilled workforce and competitive business environment, Ontario is a prime location for businesses in the life sciences sector to invest and grow. We congratulate OmniaBio on this exciting milestone and look forward to seeing their facility drive further advancements across the province's life sciences ecosystem,” Hon. Vic Fedeli, Minister of Economic Development, Job Creation and Trade noted.

OmniaBio Inc., a subsidiary of CCRM, is a contract development and manufacturing organization (CDMO) conducting process development and producing gene-modified cells and viral vectors for Phase I clinical trials to commercial-scale manufacturing.

“Invest Ontario welcomes the opportunity to partner with OmniaBio Inc. in this transformative project that will boost life sciences talent, innovation and supply chain capacity,” added Trevor Dauphinee, CEO, Invest Ontario. “Our team looks forward to building on today’s announcement as we pursue strategic investments with homegrown champions and global leaders to drive Ontario growth and innovation.”

Exclusive Research